

NG25

Catalog No: tcsc0875



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

1315355-93-1

Formula:

$C_{29}H_{30}F_3N_5O_2$

Pathway:

NF-κB;MAPK/ERK Pathway;MAPK/ERK Pathway

Target:

TAK1;MAP3K;MAP4K

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

537.58


Product Description

NG25 is a potent dual **TAK1** and **MAP4K2** inhibitor, with **IC₅₀s** of 149 nM and 21.7 nM, respectively.

IC50 & Target: IC50: 21.7 nM (MAP4K2), 149 nM (TAK1), 12.9 nM (LYN), 56.4 nM (CSK)^[1]

In Vitro:

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC_{50} s of 149 nM and 21.7 nM, respectively. NG25 also potently suppresses several kinases such as LYN, CSK, FER, p38 α , ABL, ARG and SRC, with IC_{50} s of 12.9, 56.4, 82.3, 102, 75.2, and 113 nM, respectively^[1]. NG25 is very potent suppressor of CpG B- or CpG A-stimulated secretion of IFN α and CL097-stimulated secretion of IFN β , with complete inhibition by 400 nM^[2]. NG25 treatment reduces cell viability of all tested breast cancer cell lines in a dose dependent manner. NG25 (2 μ M) enhances the cytotoxic effect of Dox on breast cancer cells^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!